Patients with IDH1 mutant and 1p19q codeletion exhibit better prognosis than those with IDH1-wild-type and 1p19q non-codeletion gliomas (Hartmann et al., 2010; Hainfellner et al., 2014). This evidence concerns the gene IDH1 and central nervous system cancer.